EPISODE · May 13, 2022 · 17 MIN
Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma
from Oncology Data Advisor · host i3 Health
In honor of Melanoma Awareness Month, Dr. Shaheer Khan, Assistant Professor of Medicine at Columbia University Irving Medical Center, shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.
What this episode covers
In honor of Melanoma Awareness Month, Dr. Shaheer Khan, Assistant Professor of Medicine at Columbia University Irving Medical Center, shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.
NOW PLAYING
Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 13, 2026 ·3m
Jun 12, 2026 ·3m
Jun 11, 2026 ·3m